Chemotherapy before stem cell transplant for NK/T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy drugs given before a donor stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this preconditioning helps the transplant work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have NK/T-cell lymphoma that is stage III/IV and in remission after treatment, stage II that has come back or not responded to treatment but is now in remission, NK-cell lymphoma/leukemia in remission, or disease that has come back or not responded to treatment.
- You have a suitable donor: a related donor with at least half of certain genetic markers matching, or an unrelated donor with at least 80% matching.
- Your overall health is good enough for a transplant (score of 2 or less on a common health index, and you can carry out daily activities with little or no help).
- Your heart, lungs, liver, and kidneys are working well enough as shown by specific tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—selinexor and azacitidine—given as a maintenance therapy after a donor stem cell transplant for NK/T-cell lymphoma. The goal is to help prevent the lymphoma from coming back.
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
This study tests a stronger but safer chemo preparation before a stem cell transplant for people with T-cell lymphoma that has returned or not responded to treatment.
This Phase 2 study tests an allogeneic (donor) stem cell transplant for people with T-cell or NK-cell lymphomas that came back or did not respond to prior treatment. It may help by giving you new, healthy immune cells that can attack the cancer.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.